NEUMEGA® (oprelvekin)

LENGTH OF AUTHORIZATION: Up to six months

INITIAL REVIEW CRITERIA (ALL OF THE FOLLOWING MUST BE TRUE):
• Patient must be ≥18 years old; safety and efficacy have not been established in pediatric patients.
• Patient must have a confirmed diagnosis of a nonmyeloid malignancy (examples of myeloid malignancies would be any form of leukemia).
• Clinical notes document patient is at high risk for severe thrombocytopenia based on previous history of severe thrombocytopenia with the same chemotherapeutic regimen (platelet count less than 20,000/µL).
• Oprelvekin therapy will begin no sooner than six hours following the completion of chemotherapy and will be discontinued at least two days prior to starting the next dose of chemotherapy (duration of therapy is based on monitoring recovery of platelet count and usually is approximately a 10 to 21 day cycle). Dosing beyond 21 days per treatment course is not recommended.

CONTINUATION OF THERAPY
• Patient continues to receive myelosuppressive chemotherapy for a nonmyeloid malignancy and is tolerating oprelvekin.

DOSING & ADMINISTRATION:
• In adult patients without severe renal impairment, the dose is 50 micrograms/kilogram given subcutaneously once daily.
• The recommended dose in adults with severe renal impairment (creatinine clearance < 30 mL/min) is 25 mcg/kg given subcutaneously once daily.
• Dosage Form: Single 5 mg lyophilized powder in vials. Neumega is packaged in boxes with one oprelvekin 5 mg vial and one syringe containing one mL of Sterile Water for Injection, USP for reconstitution.

Reference:
Neumega [package insert] Wyeth Pharmaceuticals Inc; Philadelphia PA; January 2011